决定异体 CAR T 细胞排斥与扩增的细胞和分子机制

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

我如何治疗浆细胞白血病

How I treat plasma cell leukemia.

内源性 CD28 驱动 CAR-T 细胞在骨髓瘤与淋巴瘤模型中的持续活性

Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

CXCR4 修饰通过改善 B 细胞恶性肿瘤的肿瘤追踪与骨髓归巢增强 CAR-T 疗效

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.

基于 BAFF 的三功能 T 细胞衔接器触发针对 B 细胞恶性肿瘤的强效抗肿瘤免疫

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

事实与希望：CAR-T 细胞治疗与非霍奇金淋巴瘤免疫构成

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

抗 BCMA CAR-T 细胞治疗后 CAR+ T 细胞淋巴瘤的靶向治疗

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.